Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

20,513 total articles

Septerna to Participate in Upcoming Investor Conferences

Septerna to Participate in Upcoming Investor Conferences

Septerna, Inc., a clinical-stage biotech focusing on GPCR drug discovery, announced management's participation in two major healthcare investor conferences in September 2026, including live webcasts. The company highlights its proprietary technology platform and diverse pipeline targeting endocrinology, immunology, inflammation, and metabolic disea…

Aduro Clean Technologies Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Business Update

Aduro Clean Technologies Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Business Update

Aduro Clean Technologies Inc. reported its fourth quarter and fiscal 2026 results highlighting substantial investments in pilot plant operations, engineering, and project development. The company transitioned its Next Generation Process Pilot Plant into structured operations and progressed its First-of-a-Kind program. Aduro strengthened its financi…

Biometric Identity Security Provider BIO-key Participates at H.C. Wainwright Global Investment Conference Sept. 15th and 17th

Biometric Identity Security Provider BIO-key Participates at H.C. Wainwright Global Investment Conference Sept. 15th and 17th

BIO-key International, a leader in biometric identity and access management solutions, announced that CEO Michael DePasquale will participate in virtual meetings and present at the H.C. Wainwright Global Investment Conference in September 2026. The company's presentation will be available on demand to registered attendees, highlighting its biometri…

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions has been awarded a $24 million contract modification by BARDA, part of the U.S. Department of Health and Human Services, to supply its CYFENDUS® anthrax vaccine. This contract supports the U.S. government's ongoing anthrax preparedness efforts amid biological threats. CYFENDUS®, FDA-approved in 2023 for post-exposure prophylax…

Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.09 Per Share for September 2026

Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.09 Per Share for September 2026

Kayne Anderson Energy Infrastructure Fund, Inc. declared a monthly distribution of $0.09 per common share payable on September 30, 2026. The fund focuses on energy infrastructure securities and aims to provide high after-tax returns with an emphasis on cash distributions. Distribution amounts may vary and are subject to Board approval and financial…

3 E Network Secures $1.2 Million Enterprise DDR4 Memory Sales Order

3 E Network Secures $1.2 Million Enterprise DDR4 Memory Sales Order

3 E Network Technology Group Limited announced that its wholly owned subsidiary secured a $1.2 million sales order for enterprise-grade DDR4 memory chips. This order demonstrates the company's capabilities in hardware supply amid growing IT infrastructure upgrades and provides additional revenue to support its AI infrastructure R&D efforts. The ord…

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), announced an expanded three-phase program with Yuva Biosciences to advance four AI-discovered compounds toward lead nomination for developing potential therapies in cardiac diseases and obesity. The program builds upon positive Phase III results and aims to de-risk and narrow ca…

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio and Virotek announced a letter of intent to establish an exclusive U.S. distribution partnership where Kala will market and distribute Virotek's genetic testing program for ophthalmology. This collaboration aligns with Kala's strategic focus on eye care and provides a near-term commercial revenue opportunity while extending Kala's reach in…

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine Inc. has initiated Phase IIa of its Phase I/IIa clinical trial evaluating CMND-100, a non-hallucinogenic psychedelic-derived therapeutic candidate, for the treatment of Alcohol Use Disorder (AUD). Six patients have been enrolled so far across medical centers in Israel, marking progression into the multiple-dose treatment phase fo…

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics, a US-based commercial-stage biotech company specializing in autoimmune kidney diseases, will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference in September 2026. The company's management aims to engage investors through fireside chats and one-on-one meetings, highlighting their…

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis announced that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, robust responses in the prespecified interferon gene signature-high (IFNGS-high) subgroup, representing most moderate-to-severe SLE cases, support …

KANZHUN LIMITED Announces Change of Directors’ Executive Positions

KANZHUN LIMITED Announces Change of Directors’ Executive Positions

KANZHUN LIMITED, a leading Chinese online recruitment platform, announced the rotation of its president position effective September 1, 2026. Mr. Xu Chen steps down as president but remains as executive director and Chief Marketing Officer, while Mr. Tao Zhang takes over as rotating president alongside his roles as executive director and Chief Tech…

BridgeBio to Participate in September Investor Conferences

BridgeBio to Participate in September Investor Conferences

BridgeBio Pharma, a biopharmaceutical company focused on genetic condition medicines, announced that its management will participate in several upcoming healthcare investor conferences in September 2026. These include Wells Fargo, Cantor Global, Morgan Stanley, and Bernstein Insights conferences. The company aims to communicate its developments and…

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx Inc., a US commercial-stage biopharmaceutical company, has announced its participation in several major investor conferences in New York during September 2026, including Citi, Cantor, and Morgan Stanley healthcare events. The company will host fireside chats and investor meetings, providing updates on its commercial products IBSRELA and XPH…

Streamex Corp. Appoints Laura Kiernan as Head of Investor Relations

Streamex Corp. Appoints Laura Kiernan as Head of Investor Relations

Streamex Corp., a Nasdaq-listed technology company specializing in tokenization of commodity assets, appointed Laura Kiernan as Head of Investor Relations. Kiernan brings over 30 years of capital markets experience to lead investor relations strategy, aiming to bridge the value of Streamex's platform with market perception. The move supports Stream…

Telesat Government Solutions and Cailabs Collaborate on Secure Optical Connectivity for Government Missions

Telesat Government Solutions and Cailabs Collaborate on Secure Optical Connectivity for Government Missions

Telesat Government Solutions, a US-based subsidiary of Telesat Corporation (TSAT), has signed a strategic collaboration with Cailabs US, Inc. to integrate secure, resilient, high-capacity optical space-to-ground connectivity for U.S. Government and allied missions. The partnership aims to combine Telesat's Lightspeed LEO satellite network with Cail…